New! Hepatitis C treatment factsheets – telaprevir, boceprevir and sofosbuvir

Greta Hughson
28 May 2014

Three new factsheets on direct-acting antivirals used to treat hepatitis C are available now on You can read the factsheets online or download them as print-friendly PDFs.

New hepatitis C drugs

If you have an interest in hepatitis C treatment research, you will have noticed a huge amount of activity in the last few years. There are new drugs in development and that means lots of studies, looking at how effective they are for different people, how safe they are, what side-effects people experience and much more. All of these studies produce lots of important data which should inform the decisions people make about treatment.

It is an exciting time for hepatitis C treatment, as the newer drugs coming to the market generally have fewer side-effects and are easier to take than the previous standard treatments. However, the wealth of detailed information on all these new drugs can be overwhelming. If you’re someone living with hepatitis C, or someone who cares for people living with hepatitis C, where do you start?

We are offering you an answer – start with our new factsheets!

Hepatitis C treatment factsheets

We have produced three factsheets, on key new direct-acting antiviral drugs. Each factsheet gives information such as how the drug works, who can use it, how it is taken, how effective it is and the side-effects reported by people taking it.

Each factsheet is available to read online, or to download as a print-friendly PDF. Please print and share these factsheets with anyone you think would find them helpful.

For more information

We launched these factsheets at the recent International Liver Congress in London and the response was positive and enthusiastic! If you have any feedback, please do let us know. You can email us at

Thank you to everyone involved in the development of these resources. We would particularly like to thank Liz Highleyman ( for her work on these factsheets.

We are grateful to Janssen for funding the development of these factsheets. Janssen has had no editorial control over the content.